Pengaruh ESG Risk Rating dan Kinerja Keuangan terhadap Stock Return: Studi Empiris terhadap Perusahaan yang Terdaftar pada Bursa Efek Indonesia dalam Indeks IDX ESG Leaders
JURNAL EKSPLORASI AKUNTANSI · 30.05.2026 · 8 (2) · 724-737
DOI: 10.24036/jea.v8i2.2594 ↗Kurz gefasst
Fachartikel in der Zeitschrift JURNAL EKSPLORASI AKUNTANSI, online erschienen am 30.05.2026. Verfasst von Afifi Putri und 1 weiteren Autor:innen.
Abstract (Originalsprache)
This study aims to determine the effect of ESG Risk Rating and financial performance on Stock Return. This study uses a sample of companies listed on the IDX ESG Leaders index from 2020-2023. The sampling technique uses is purposive sampling. The analysis technique used is in the form of multiple linear analysis and processed using SPSS ver 26, with ESG Risk Rating and financial performance as the independent variable and Stock Return as a dependent variable the result show that ESG Risk Rating and financial performance that measure by ROA has a positive and significant effect on Stock Return. while financial performance that measure by EPS do not have an effect.
Zitieren
APA
Putri, A., & Mulyani, E. (2026). Pengaruh ESG Risk Rating dan Kinerja Keuangan terhadap Stock Return: Studi Empiris terhadap Perusahaan yang Terdaftar pada Bursa Efek Indonesia dalam Indeks IDX ESG Leaders. JURNAL EKSPLORASI AKUNTANSI, 8(2), 724-737. https://doi.org/10.24036/jea.v8i2.2594
Vancouver
Putri A, Mulyani E. Pengaruh ESG Risk Rating dan Kinerja Keuangan terhadap Stock Return: Studi Empiris terhadap Perusahaan yang Terdaftar pada Bursa Efek Indonesia dalam Indeks IDX ESG Leaders. JURNAL EKSPLORASI AKUNTANSI. 2026;8(2):724-737. doi:10.24036/jea.v8i2.2594
BibTeX
@article{Putri2026,
author = {Putri, Afifi and Mulyani, Erly},
title = {Pengaruh ESG Risk Rating dan Kinerja Keuangan terhadap Stock Return: Studi Empiris terhadap Perusahaan yang Terdaftar pada Bursa Efek Indonesia dalam Indeks IDX ESG Leaders},
journal = {JURNAL EKSPLORASI AKUNTANSI},
year = {2026},
volume = {8},
number = {2},
pages = {724--737},
doi = {10.24036/jea.v8i2.2594}
}
EUVIMED